The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 21, 2023

Filed:

Aug. 02, 2018
Applicant:

Bioatla, Inc., San Diego, CA (US);

Inventor:

Jay M. Short, Jackson, WY (US);

Assignee:

BioAtla, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/10 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 14/735 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1058 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70503 (2013.01); C07K 14/70521 (2013.01); C07K 14/70535 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C07K 16/2863 (2013.01); C12N 15/102 (2013.01); A61K 35/17 (2013.01); A61K 38/00 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/572 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01);
Abstract

This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region including a multispecific antibody evolved from a wild-type antibody or a fragment thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type antibody or the fragment thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type antibody or the fragment thereof. A method for using the chimeric antigen receptor and cytotoxic cells for cancer treatment is also provided. A method for producing the chimeric antigen receptor is also provided.


Find Patent Forward Citations

Loading…